慶應医学会例会

下記のとおり例会を開催いたしますので、ふるってご来聴くださいますようお願い申し上げます。

日 時 2018 年 1 月 25 日 (水) 17 : 00
場 所 未定
演 題 na
  Daniel Mucida Dr
The rockefeller University
担 当

消化器内科 教室
責任者:金井隆典 教授
担当者:筋野智久 先生 (内線 62384)

 
  以上
日 時 2017 年 11 月 24 日 (金) 14 : 00
場 所 総合医科学研究棟1階ラウンジ
演 題 Immunity to gut commensal fungi in health and disease
  Dr. Iliyan D Iliev
Weill Cornell Medical College
担 当

微生物学・免疫学教室 教室
責任者:本田賢也 教授
担当者:(内線 61202)

 
  以上
日 時 2017 年 11 月 10 日 (金) 18 : 00
場 所 リサーチパーク1階ラウンジ
演 題 Cellular Reprogramming Approaches to Cardiovascular Disease
  Deepak Srivastava MD
Gladstone Institute of Cardiovascular Disease
担 当

循環器内科 教室
責任者:福田恵一 教授
担当者:家田真樹 先生 (内線 61421)

 
  以上
日 時 2017 年 11 月 7 日 (火) 18 : 00
場 所 総合医科学研究棟1Fラウンジ(予定)
演 題 The human skin microbiome and atopic dermatitis
  Heidi H. Kong M.D., M.H.Sc.
Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH
担 当

皮膚科学 教室
責任者:天谷雅行 教授
担当者:大内健嗣 先生 (内線 62411)

 
  以上
日 時 2017 年 10 月 31 日 (火) 19 : 00
場 所 総合医科学研究棟 1階ラウンジ
演 題 Pharmacological therapies for schizophrenia - recent advances and future perspectives
  W. Wolfgang Fleischhacker M.D.
Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck

Four main topics have shaped research and clinical practice in the past decade. These have dealt with: 1) Early intervention in the prediagnostic stage, i.e. the attenuated psychosis syndrome; 2) Novel neurobiological treatment targets; 3) The introduction of alternative formulations; 4) Attempts to predict treatment response.
1) In a number of RCTs, researchers have investigated whether treating prodromal symptoms of schizophrenia helps to reduce the conversion risk to full-blown schizophrenia. Results are ambiguous and the discussion on whether or not an intervention at the stage is justified is ongoing.
2) Following the enhanced understanding of the pathophysiology of schizophrenia, also with respect to specific symptom domains, pharmacological targets beyond D2 receptor antagonism have been explored. Much work and enthusiasm has revolved around nicotinergic and glutamatergic compounds, so far with mostly discouraging results.
3) Several new generation antipsychotics have become available as long-acting depot formulations. All of them have demonstrated a significant positive impact on relapse rates in placebo controlled studies. Whether these compounds also have advantages over first generation depots and / or oral antipsychotics is still debated and investigated.
Lastly, attempts from various perspectives, including genetics and neuroimaging, have investigated whether it is possible to predict treatment response and drug safety. Although some look promising, they have not yet reached a stage in which they can be applied to everyday clinical practice. What has become clear though, is, that early non response predicts late non response, leading to the recommendation to switch antipsychotics much earlier than stated in most treatment guidelines.
担 当

精神・神経科学教室 教室
責任者:三村將 教授
担当者:内田裕之 先生 (内線 62454)

 
  以上
日 時 2017 年 10 月 30 日 (月) 18 : 30
場 所 3号館北棟1階ラウンジ
演 題 New perspective on the treatment of intractable gastrointestinal cancer: Role of combination therapies
  Dan G. Duda D.M.D., Ph.D.
Investigator, Massachusetts General Hospital Research Institute Associate Professor of Tumor Biology, Harvard Medical School Translational Research Director for GI Radiation Oncology Edwin L. Steele Laboratories for Tumor Biology Massachusetts General Hospital

Unresectable gastrointestinal cancers, such as gastric, hepatocellular, biliary tract or pancreatic carcinomas, are often resistant to anti-cancer systemic therapies, and often recur locally or even after aggressive local therapies leading to dismal survival rates. Recent developments in oncology, have offered renewed hoped for the development of more efficacious therapies. For example, our understanding of the oncogenic drivers in carcinogenesis has increased exponentially, and may potentially allow personalization of therapy. In addition, a great interest has been recently to target immune checkpoints, and unleash the potential of the immune system against cancers. Finally, new radiation techniques (proton therapy) allow delivery of curative doses in a safely manner. However, optimal translation of these new therapeutic approaches will require a concerted effort in clinical trials and in preclinical studies. I will present results from clinical correlative studies and preclinical models of these diseases performed at our institution and in collaboration with other American and European investigators. The insights gained from this, bench-to-the-bedside and back, approach raise the hope for a more efficient development of targeted agents in gastrointestinal cancers, with the goal of increasing survival in patients afflicted with these aggressive and deadly diseases.
担 当

外科学教室(一般・消化器) 教室
責任者:北川雄光 教授
担当者:福田和正 先生 (内線 62334)

 
  以上
日 時 2017 年 10 月 27 日 (金) 17 : 00〜
場 所 東校舎1F会議室
演 題 Tumor suppression mechanisms of SOCS1
  Subburaj Ilangumaran, Ph.D.
Professor, Dept. Pediatrics Immunology Division University of Sherbrooke, Canada

(要旨)
Clinical and experimental data strongly support the notion that SOCS1 is a tumor suppressor protein. However, molecular mechanisms underlying the tumor suppressor function of SOCS1 are far from clear. Using a murine liver cancer model, we have shown that SOCS1 regulates oncogenic MET signaling and prevents CDKN1A, which normally functions as a tumor suppressor, from gaining oncogenic potential. Our recent findings indicate that SOCS3, which exerts tumor suppression independently of SOCS1, is also modulated by the loss of SOCS1 in hepatocytes.

演 題 IL-17 Signaling in Autoimmunity and Cancer
  Xiaoxia Li, Ph.D.
Professor, Cleveland Clinic Lerner Research Institute, Ohio, USA

(要旨)
IL-17A is responsible for protection from multiple forms of infectious disease (particularly fungal infection) but are also associated strongly with autoimmune diseases and cancer. Since the discovery of this connection (first published in 2007) we have continued to dissect the molecular regulation of IL-17-mediated physiology and pathophysiology and have identified critical determinants that enable this pathway to connect to multiple downstream endpoints. Such functional diversity and the knowledge of responsible molecular controls have allowed us to develop candidate inhibitors that have shown significant potential for therapeutic application in pre-clinical studies.
担 当

責任者:微生物学・免疫学教室 吉村 昭彦 (内線61224)

  以上
日 時 2017 年 10 月 27 日 (金) 13 : 00
場 所 総合医科学研究棟 1階ラウンジ
演 題 Microbiota and the eye: the good and the bad
  Rachel R Caspi Dr
National Institutes of Health (NIH)
担 当

微生物学・免疫学教室 教室
責任者:本田賢也 教授
担当者:(内線 61202)

 
  以上
日 時 2017 年 10 月 3 日 (火) 16 : 30
場 所 総合医科学研究棟5階 会議室5
演 題 Form Follows Function: Systems Ecology of the Human Gut Microbiome
  Paul Wilmes Dr.
Luxembourg Centre for Systems Biomedicine, University of Luxembourg
担 当

微生物学・免疫学教室 教室
責任者:本田賢也 教授
担当者:(内線 62696)

 
  以上
日 時 2017 年 9 月 11 日 (月) 19 : 00
場 所 総合医科学研究棟1階 ラウンジ
演 題 Stem Cells and Genomics for Precision Cardiovascular Medicine
  Joseph C Wu MD, PhD, Professor
Stanford University
担 当

内科学(循環器)教室
責任者:福田恵一 教授
担当者:福田恵一 先生 (内線 61420)

 
  以上
日 時 2017 年 9 月 1 日 (金) 17 : 00
場 所 総合医科学研究棟1階 ラウンジ
演 題 Checkpoint inhibition in melanoma and solid tumors: - What has it taught us about the efficacy and side effects of immunotherapy for cancer?
  Jeffrey S Weber MD, PhD
Deputy Director, Laura and Isaac Perlmutter Cacncer Center, Professor of Medicine, NYU Langone Medical Center
担 当

先端研(細胞)教室
責任者:河上 裕 教授
担当者:(内線 62708)

 
  以上

†先頭へ

関連病院会 クリニック情報 住所変更依頼 HOME